about
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsBreast cancer in the personal genomics eraBiomarkers in triple negative breast cancer: A reviewA quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.Current advances in biomarkers for targeted therapy in triple-negative breast cancerNuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancerAstemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapyHow reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and GynecopathologistsBreast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian populationOverexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment.Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.Who would have thought a single Ki67 measurement would predict long-term outcome?The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling.Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ)Molecular sentinel-on-chip for SERS-based biosensingMultiplex detection of breast cancer biomarkers using plasmonic molecular sentinel nanoprobesCells of renin lineage take on a podocyte phenotype in aging nephropathy.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancerSalicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.A novel model for Ki67 assessment in breast cancer.Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice.Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Netrin-1 promotes glioma growth by activating NF-κB via UNC5AKi67: a time-varying biomarker of risk of breast cancer in atypical hyperplasiaCirculating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemiaKi67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignanciesRNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cellsKi-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo.Recent advances in managing triple-negative breast cancersProspective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycosideThe role of TGFBI in mesothelioma and breast cancer: association with tumor suppression.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
P2860
Q24297639-8436AE7E-27CC-4792-BEF5-7AD698E21ADBQ24602679-6605DFB0-8956-444A-98A5-E77D1944549EQ26775094-51015B3E-3012-480C-969B-E13A0445A588Q27335560-67C75BCE-2587-4BA7-AE67-87B448AE6992Q28074202-FFD8D36A-E21F-4D9C-A2C8-5B06F9BB89ABQ28247712-B38CD2BD-5D4D-496F-B763-6A468270F457Q28483692-103B4DF9-903A-483E-A3D5-00B6DD3677C2Q28729183-87026C7B-24E7-4B78-B71E-085FAC2787B3Q29006708-18DB52CC-21A3-4D91-BF4F-9DE50B59A3AAQ30525568-E7A5ACDB-F03C-44F9-B8E0-A5A8F040C8C4Q30652903-1840791B-3687-4862-AF0D-7351662C5060Q30938639-383A2DDF-D668-40C2-85CC-078BA7EE7F66Q31134354-5588ADA8-3129-424A-A573-DC038DA0B037Q33368855-E4EADB3A-A28D-4B34-AC8C-BEB49DF91D4EQ33555522-0B08E55E-435C-4B07-84F9-1DF8B0BFA8C4Q33575622-27B77B30-B8A0-4A11-8850-F19DA89CED73Q33601161-1830D2A4-9034-4A35-B416-E6DD41BE8190Q33616956-E28A1578-4E3A-470A-B708-A04B1051F8CCQ33616968-17244DA9-EB08-4C07-B57B-956C2136DF8AQ33626612-CCA2122C-6CE7-4534-A909-2C2E2CA943FBQ33692020-61C3273F-E28C-4DFE-915D-C623706A40D8Q33698446-74F1BB65-3EE7-4B97-AD53-BF8D81BBC91CQ33699104-BD85F6EA-27C6-4CA6-BF5C-AB66C564998BQ33728161-611DD594-499F-42D8-90AD-DA181E85101CQ33750115-269E71F6-CFBE-453E-9D49-371BA7874611Q33801255-3181ABE5-6879-4CFB-900E-7A55930C6B02Q33830630-C39D0B09-E566-4189-8930-30EB56B3F214Q33843751-F3674AA0-51CB-46AA-9DF7-E9E6E43DED78Q33905507-318B4FF0-1E49-4E88-9781-00A07CF88E13Q33932379-1BF89B25-7E9E-4337-B671-FADF64FC597BQ33942256-299456BB-8277-4975-B62B-196396AB0527Q33984087-871700ED-1F1C-4EF1-A190-848EE5CB2DDDQ34003699-FAC0BE64-D49F-47C0-8AF5-F34A55B96457Q34075234-C30AA9A3-52D8-4645-A085-FA20B2FD6B72Q34127775-75837323-9842-491D-AABD-F8E82CFE5BAFQ34167327-131351CF-9354-4D37-94D4-96CACDB997DAQ34190743-8E035D3F-C5D8-425D-8C44-AAF3BE381EB9Q34203765-B8868505-EFA3-4D46-B026-ECA7D8BD582EQ34303247-6C724311-431F-472E-81F4-C87DB4CA7D54Q34315684-B06986B8-EE81-4AB2-B85D-ABC9B81013FF
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Proliferation marker Ki-67 in early breast cancer.
@ast
Proliferation marker Ki-67 in early breast cancer.
@en
type
label
Proliferation marker Ki-67 in early breast cancer.
@ast
Proliferation marker Ki-67 in early breast cancer.
@en
prefLabel
Proliferation marker Ki-67 in early breast cancer.
@ast
Proliferation marker Ki-67 in early breast cancer.
@en
P356
P1476
Proliferation marker Ki-67 in early breast cancer.
@en
P2093
Ander Urruticoechea
Ian E Smith
P304
P356
10.1200/JCO.2005.07.501
P407
P577
2005-10-01T00:00:00Z